Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 350-362

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early glycaemic control among patients with type 2 diabetes and initial glucose‐lowering treatment: a 13‐year population‐based cohort study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 771-780

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite

Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus

By Jung Jin   Kaku Kohei   Kim Jae   Kim Jung-Ryul   Ko Jae-Wook   Lee Soo-Youn   Huh Wooseong  

Advances in Therapy, Vol. 30, Iss. 11, 2013-11 ,pp. : 1018-1029

Springer Publishing Company

Access to resources Recommend Favorite

Prescribing practices and clinical predictors of glucose‐lowering therapy within the first year in people with newly diagnosed Type 2 diabetes

By  

DIABETIC MEDICINE, Vol. 32, Iss. 12, 2015-12 ,pp. : 1546-1554

John Wiley & Sons Inc

Access to resources Recommend Favorite